Arcutis Biotherapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $376.1 | $196.5 | $59.6 | $3.7 | $0.0 |
| Operating income | -$12.2 | -$128.4 | -$241.1 | -$301.6 | -$206.5 |
| Net income | -$16.1 | -$140.0 | -$262.1 | -$311.5 | -$206.4 |
| Balance Sheet | |||||
| Total debt | $100.0 | $100.0 | $200.0 | $200.0 | $75.0 |
| Cash Flow Statement | |||||
| Free cash flow | -$6.3 | -$112.3 | -$247.5 | -$258.0 | -$175.6 |
Shares outstanding 125.7M · Free float 79.2%
Annual filing data through FY ended December 31, 2025; float as of October 4, 2026.